EA201992316A1 - Композиции и способы для диагностики рака предстательной железы - Google Patents
Композиции и способы для диагностики рака предстательной железыInfo
- Publication number
- EA201992316A1 EA201992316A1 EA201992316A EA201992316A EA201992316A1 EA 201992316 A1 EA201992316 A1 EA 201992316A1 EA 201992316 A EA201992316 A EA 201992316A EA 201992316 A EA201992316 A EA 201992316A EA 201992316 A1 EA201992316 A1 EA 201992316A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- compositions
- methods
- prostate cancer
- diagnostic
- progastrin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57434—Specifically defined cancers of prostate
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5748—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96402—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from non-mammals
- G01N2333/96405—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from non-mammals in general
- G01N2333/96408—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from non-mammals in general with EC number
- G01N2333/96411—Serine endopeptidases (3.4.21)
Abstract
Настоящее изобретение относится к композициям и способам для диагностики рака предстательной железы in vitro, где указанные композиции содержат антитело, связывающееся с прогастрином, и указанные способы включают применение антитела, связывающегося с прогастрином.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17305381 | 2017-03-30 | ||
PCT/EP2018/058330 WO2018178352A1 (en) | 2017-03-30 | 2018-03-30 | Compositions and methods for detecting prostate cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201992316A1 true EA201992316A1 (ru) | 2020-03-05 |
Family
ID=58501413
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201992316A EA201992316A1 (ru) | 2017-03-30 | 2018-03-30 | Композиции и способы для диагностики рака предстательной железы |
EA201992318A EA201992318A1 (ru) | 2017-03-30 | 2018-03-30 | Композиции и способы для диагностики и лечения рака предстательной железы с использованием молекулы, связывающей прогастрин |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201992318A EA201992318A1 (ru) | 2017-03-30 | 2018-03-30 | Композиции и способы для диагностики и лечения рака предстательной железы с использованием молекулы, связывающей прогастрин |
Country Status (12)
Country | Link |
---|---|
US (2) | US11644468B2 (ru) |
EP (2) | EP3601343B1 (ru) |
JP (2) | JP7071994B2 (ru) |
KR (2) | KR102317805B1 (ru) |
CN (2) | CN110945025B (ru) |
AU (2) | AU2018242152B2 (ru) |
BR (2) | BR112019020413A2 (ru) |
CA (2) | CA3058267C (ru) |
EA (2) | EA201992316A1 (ru) |
ES (2) | ES2921775T3 (ru) |
SG (2) | SG11201908997UA (ru) |
WO (2) | WO2018178363A1 (ru) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3084687C (en) * | 2017-12-05 | 2024-01-02 | Progastrine Et Cancers S.A R.L. | Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer |
KR20200125581A (ko) | 2017-12-08 | 2020-11-04 | 이씨에스-바이오트래커 에스에이알엘 | 암 진단에서 방사성표지된 프로가스트린 |
TW201940881A (zh) | 2018-01-26 | 2019-10-16 | 瑞士商Ecs前胃泌激素公司 | 在癌症診斷中結合前胃泌激素檢測與其他癌症生物標記的技術 |
KR20200144541A (ko) | 2018-02-27 | 2020-12-29 | 이씨에스-프로가스트린 에스에이 | 면역치료요법용 생체표지자로서 프로가스트린 |
CN111518908B (zh) * | 2020-05-18 | 2023-10-17 | 奥尔文泰生物科技(杭州)有限公司 | 尿液***癌标志物组合及其在制备精准诊断试剂中的用途 |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
GB8924581D0 (en) | 1989-11-01 | 1989-12-20 | Pa Consulting Services | Bleaching of hair |
DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
JPH05244982A (ja) | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化b−b10 |
ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
PT752248E (pt) | 1992-11-13 | 2001-01-31 | Idec Pharma Corp | Aplicacao terapeutica de anticorpos quimericos e marcados radioactivamente contra antigenios de diferenciacao restrita de linfocitos b humanos para o tratamento do linfoma de celulas b |
DK0708656T3 (da) * | 1993-04-27 | 2002-12-02 | United Biomedical Inc | Antigene LHRH peptidkonstruktioner og universelle syntetiske immunstimulatorer til vacciner |
EP0822830B1 (en) | 1995-04-27 | 2008-04-02 | Amgen Fremont Inc. | Human anti-IL-8 antibodies, derived from immunized xenomice |
AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
CA2722378C (en) | 1996-12-03 | 2015-02-03 | Amgen Fremont Inc. | Human antibodies that bind tnf.alpha. |
JP3876002B2 (ja) | 1997-04-14 | 2007-01-31 | ミクロメート・アクチエンゲゼルシャフト | 抗ヒト抗原受容体を産生するための斬新な方法およびそれらの使用 |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
WO1999018210A2 (en) * | 1997-10-07 | 1999-04-15 | Corixa Corporation | Compounds and methods for immunotherapy and immunodiagnosis of prostate cancer |
ES2277846T3 (es) * | 1999-07-29 | 2007-08-01 | Medarex, Inc. | Anticuerpos monoclonales humanos para antigeno prostatico especifico. |
US20030232399A1 (en) * | 2000-06-14 | 2003-12-18 | Robertson John Forsyth Russell | Cancer detection methods and reagents |
JP2003111595A (ja) * | 2001-06-25 | 2003-04-15 | Kyogo Ito | 腫瘍抗原 |
JP2003261460A (ja) * | 2002-03-08 | 2003-09-16 | Kyowa Hakko Kogyo Co Ltd | 肺選択的癌転移の診断薬および治療薬 |
EP1391213A1 (en) | 2002-08-21 | 2004-02-25 | Boehringer Ingelheim International GmbH | Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents |
EP1753442A2 (en) * | 2004-06-10 | 2007-02-21 | Regeneron Pharmaceuticals, Inc. | Method of administering and using vegf inhibitors for the treatment of human cancer |
CA2580965C (en) | 2004-09-22 | 2014-04-08 | Receptor Biologix, Inc. | Monoclonal antibodies to progastrin |
JP4950880B2 (ja) * | 2005-04-13 | 2012-06-13 | 株式会社先端生命科学研究所 | ガストリン放出ペプチド前駆体に対する抗体およびその使用 |
EA201791876A1 (ru) * | 2009-10-16 | 2018-01-31 | Ле Лаборатуар Сервье | Моноклональные антитела к прогастрину и их применение |
US20130095503A1 (en) * | 2010-01-05 | 2013-04-18 | University Of Cincinnati | Serum spla2-iia as diagnosis marker for prostate and lung cancer |
US9217032B2 (en) | 2010-01-08 | 2015-12-22 | Les Laboratoires Servier | Methods for treating colorectal cancer |
US8900588B2 (en) | 2010-01-08 | 2014-12-02 | Les Laboratories Servier | Methods for treating breast cancer |
US8900817B2 (en) | 2010-01-08 | 2014-12-02 | Les Laboratories Servier | Progastrin and liver pathologies |
NZ602992A (en) | 2010-03-24 | 2014-11-28 | Servier Lab | Prophylaxis of colorectal and gastrointestinal cancer |
ES2871092T3 (es) | 2010-07-26 | 2021-10-28 | Progastrine Et Cancers S A R L | Métodos y composiciones para la terapia del cáncer de hígado |
DK3071595T3 (da) * | 2013-11-19 | 2019-07-01 | Fredax Ab | Humaniseret anti-kallikrein-2-antistof |
WO2016066671A1 (en) * | 2014-10-29 | 2016-05-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for treating resistant cancers using progastrin inhibitors |
CA2979219A1 (en) | 2015-03-10 | 2016-09-15 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind psma |
AU2017204683B2 (en) | 2015-12-31 | 2023-03-16 | Syncerus S.À R.L. | Compositions and methods for assessing the risk of cancer occurrence |
-
2018
- 2018-03-30 EP EP18713967.0A patent/EP3601343B1/en active Active
- 2018-03-30 CA CA3058267A patent/CA3058267C/en active Active
- 2018-03-30 BR BR112019020413A patent/BR112019020413A2/pt not_active IP Right Cessation
- 2018-03-30 KR KR1020197030346A patent/KR102317805B1/ko active IP Right Grant
- 2018-03-30 ES ES18713967T patent/ES2921775T3/es active Active
- 2018-03-30 CN CN201880034255.6A patent/CN110945025B/zh active Active
- 2018-03-30 JP JP2019553207A patent/JP7071994B2/ja active Active
- 2018-03-30 BR BR112019020414A patent/BR112019020414A2/pt not_active Application Discontinuation
- 2018-03-30 CA CA3058263A patent/CA3058263C/en active Active
- 2018-03-30 WO PCT/EP2018/058344 patent/WO2018178363A1/en unknown
- 2018-03-30 EA EA201992316A patent/EA201992316A1/ru unknown
- 2018-03-30 US US16/498,557 patent/US11644468B2/en active Active
- 2018-03-30 KR KR1020197031684A patent/KR102351556B1/ko active IP Right Grant
- 2018-03-30 SG SG11201908997U patent/SG11201908997UA/en unknown
- 2018-03-30 WO PCT/EP2018/058330 patent/WO2018178352A1/en unknown
- 2018-03-30 SG SG11201908998X patent/SG11201908998XA/en unknown
- 2018-03-30 JP JP2020503356A patent/JP7156622B2/ja active Active
- 2018-03-30 EP EP18714776.4A patent/EP3601347B1/en active Active
- 2018-03-30 ES ES18714776T patent/ES2904939T3/es active Active
- 2018-03-30 US US16/498,543 patent/US11614448B2/en active Active
- 2018-03-30 CN CN201880034272.XA patent/CN110662769B/zh active Active
- 2018-03-30 AU AU2018242152A patent/AU2018242152B2/en active Active
- 2018-03-30 AU AU2018242156A patent/AU2018242156B2/en active Active
- 2018-03-30 EA EA201992318A patent/EA201992318A1/ru unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201891983A1 (ru) | Комбинированная терапия антителами к cd73 | |
EA201891040A1 (ru) | Конъюгаты антитела, содержащие агонисты толл-подобного рецептора | |
EA201892294A1 (ru) | Антитела и композиции против tim-3 | |
EA201792221A1 (ru) | Антитела против сортилина и способы их применения | |
MX2018008934A (es) | Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso. | |
EA201992316A1 (ru) | Композиции и способы для диагностики рака предстательной железы | |
SA517381703B1 (ar) | C10orf54 - أجسام مضادة لـ واستخداماتها | |
EA201790961A1 (ru) | Перенацеливающие cd3/cd38 t-клетки гетеродимерные иммуноглобулины и способы их получения | |
EA202091540A1 (ru) | Антитела к lilrb2 | |
EA201892362A1 (ru) | Агонистические антитела, которые связываются с cd40 человека, и варианты их применения | |
MX2017004311A (es) | Anticuerpos del receptor del factor de necrosis tumoral inducido por glucocorticoide (gitr) y metodos de uso de los mismos. | |
EA201890285A1 (ru) | Антитела против pd-1, активируемые антитела против pd-1 и способы их применения | |
EA201790339A1 (ru) | Комбинированные препараты с антителами к cd40 | |
EA201792467A1 (ru) | Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены | |
EA201792589A1 (ru) | Антитела против cd123 и конъюгаты указанных антител | |
EA201691824A1 (ru) | АНТИТЕЛА ПРОТИВ EGFRvIII И ИХ ПРИМЕНЕНИЯ | |
EA201692458A1 (ru) | Анти-gitr антитела и способы их применения | |
EA201691438A1 (ru) | Антитело, которое связывается с erbb-2 и erbb-3 | |
EA201690167A1 (ru) | Гуманизованные или химерные антитела к cd3 | |
EA202190609A1 (ru) | Антитела против hla-g, композиции, содержащие антитела против hla-g, и способы применения антител против hla-g | |
MX367661B (es) | Anticuerpos anti-baff novedosos. | |
BR112018070948A2 (pt) | anticorpos anti-psma e utilização dos mesmos | |
EA201992317A1 (ru) | Композиции и способы для диагностики рака легких | |
PH12019500802A1 (en) | Antibodies that bind zika virus envelope protein and uses thereof | |
PH12020552006A1 (en) | Antibodies specific for cd3 and uses thereof |